HYPER-MASTIC research project, coordinated by IASIS PHARMA and involving reputable academics and corporations, is looking for hypertensive patients to participate in an Inter-University Study, under the auspices of the EU. For further information concerning HYPER-MASTIC, visit the website www.hyper-mastic.eu and Facebook page: Hyper-Mastic
www.hyper-mastic.eu - Facebook: Hyper-Mastic Focusing on the study of the Greek nature, IASIS PHARMA is glad to announce the launch of HYPER-MASTIC, a scientific research project to be carried out in cooperation with a team of Academic and Corporate entities. The project members are: - IASIS PHARMA a pharmaceutical industry - Chios Gum Mastic Growers Association [...]
IASIS PHARMA expands its activities focusing on Greek nature, collaborating in the establishment of Natural Products Competence Center (NPCC). NPCC is a Collaborative Innovation Formation, with the participation of 15 partners from the academic and business sectors. The project is coordinated by the Laboratory for the Utilization of Bioactive Natural Products (Department of Pharmacy, National [...]
Putting the emphasis on Authenticity. European Medicines Agency (EMA) recognized Chios Mastic as a medicine of herbal origin at the meeting that took place in London, on August 7 2015. The decision was unanimous and Chios Mastic was accepted to be included in the category of traditional herbal medicines. IASIS PHARMA played a pivotal role in the recognition of Chios Mastic both at European [...]
IASIS PHARMA and its subsidiary company Pharma Q, Chios Mastiha Growers Association and its subsidiary Mediterra, and Pharmagnose, the spin-off company of the Faculty of Pharmacy - University of Athens, join forces setting Greek nature as a focal point, by establishing the unique Chios Mastiha Research & Development Center. Manufactured with pharmaceutical industry standards, the [...]
The first meeting of the research program under the distinct title “EXANDAS” of the Marie Sklodowska Curie Actions (MSCA) program successfully took place on 21-22 April 2017. The program aims to exploit the aromatic plants’ by-products, Chios Mastic included, for the purpose of developing novel pharmaceutical products. The program’s coordinator is Assistant Prof. N. Aligiannis, [...]
IASIS PHARMA proudly announces the exclusive sponsorship of a clinical trial on the effect of Chios Mastic on blood vessels’ functionality and inflammation”. The research center conducting the study is “Alexandra” General Hospital, the results of the study are expected to be announced the last quarter of 2016.
IASIS PHARMA proudly announces the exclusive sponsorship of a clinical trial on the effect of Chios Mastic in capsules on Helicobacter Pylori. The main research center is “Laiko” Hospital of Athens. Read more about the study's latest findings here
ATHENS, 01-02/04/2016 The kick-off meeting of the research program under the distinct title “EXANDAS” of the Marie Sklodowska Curie Actions (MSCA) programs was successfully organized on 1-2 April 2016. The specific program aims to exploit the aromatic plants’ by-products such as the Chios Mastic for the purpose of developing novel pharmaceutical products. The meeting took place [...]
BRUSSELS, 10/11/2015 IASIS PHARMA proudly announces its participation in a program of H2020. The program Horizon 2020 is the financing framework of the EU for research and Innovation that will cover the period 2014-2020, with a budget of approximately 80 billion Euros. The program supports the strategy "Europe 2020" that promotes research and innovation as the [...]
